DARE database however the search involved terms used the summaries below.
Cochrane search strategy (Cochrane)

#1
intensive 
E3. Assessment of systematic review eligibility
A bespoke assessment form of systematic review eligibility for inclusion into the overview was used for documentation of full-text screening and summarised in Table E2 .
E4. Data extraction of included systematic reviews
A bespoke data extraction form was developed for independent detailed data extraction from included systematic reviews and summarised in Table E3 . (Tables E4 and E5 respectively) . 
METHODS
Protocol and registration
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the metaanalysis).
Data collection process
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Summary measures
13 State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results
14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2 ) for each meta-analysis.
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
Additional analyses
16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were prespecified.
RESULTS
Study selection 17
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Study characteristics
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
DISCUSSION
Summary of evidence
24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Conclusions
26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
Taken from Liberati et al 1 . The research question and inclusion criteria should be established before the conduct of the review.
Was there duplicate study selection and data extraction?
Should be at least two independent data extractors and a consensus procedure
Was a comprehensive literature search performed?
At least two electronic sources; must include years and databases used. Key words and/or MESH terms; search strategy should be provided. Supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts & references
Was the status of publication (i.e. grey literature) used as an inclusion criterion?
State whether or not they excluded any reports (from the systematic review), based on their publication status, language etc.
Was a list of studies (included and excluded) provided?
6. Were the characteristics of the included studies provided? Table, data from the original studies on the participants, interventions and outcomes. Characteristics analyzed e.g. age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases.
Was the scientific quality of the included studies assessed and documented?
'A priori' methods of assessment
Was the scientific quality of the included studies used appropriately in formulating conclusions?
The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and stated in formulating recommendations
Were the methods used to combine the findings of studies appropriate?
For pooled results, assess their homogeneity (i.e. Chi squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration
Was the likelihood of publication bias assessed?
(e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test).
Was the conflict of interest stated?
Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.
Taken from Shea et al 2
E6. Excluded systematic reviews
Twenty-two systematic reviews were excluded following full text assessment for eligibility (n=14, both RCT and non-RCT study designs included, but a synthesis of the findings and quality of the RCTs was not reported separately [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] ; n=4, design of non-systematic review methodology [17] [18] [19] [20] ; n=1, noneligible patient population 21 ; n=1, no eligible studies were included and therefore no data were reported 22 ; n=1 full-text not available in English 23 ; n=1 where the review was superceded by a later version 24 ). All but one of these SR pertained to the 'during ICU' phase of the recovery pathway, with one examining rehabilitation interventions post ICU discharge 7 . The 14 SR excluded for not reporting RCT and non-RCT study designs separately [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , were further examined to determine potential RCTs missing from the overview synthesis as a result of these exclusions. Table E7 presents the individual studies for each of these SR. Twenty-four RCTs were evaluated across these SR, of which 15 (62.5%) overlapped with the current overview (Table E7, highlighted in red). In total, data from 9 RCTs were not encompassed by SR in the current overview, of which 3 would have been ineligible (respiratory therapy rehabilitation intervention 25 , other nonphysical rehabilitation intervention examined -ICU follow-up clinic 26 and intensive care diary 27 ). To establish whether these non-overlapping RCTs may have influenced the findings from the overview, we reviewed the abstracts for their conclusions (Table E8) ; the findings from these RCTs were in keeping with those from the main overview. No difference in exercise capacity as 12months post ICU discharge from an exercise programme delivered during the ICU, post ICU and post hospital discharge.
Meesen et al 33 Electrical muscle stimulation delivered during ICU admission significantly attenuated muscle atrophy measured indirectly via circumferential measurements 
E8. Detail of populations reported in included systematic reviews
Summary details of individual SR population characteristics are reported in Table E10 . 55 No overall summary of participant details. These are reported in the individual study characteristics. Heterogeneity across studies.
No overall summary of gender or age. These are reported in the individual study characteristics.
Calvo-Ayala et al (2013) 53 Broad distribution of adult ICU patients evidenced by the variations in the mean APACHE (Acute Physiology and Chronic Health Evaluation) II score (range, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] No summary report for gender.
Mean age of studies' subjects (48-66 years). Connolly et al (2015) 54 Baseline characteristics between the control and intervention groups in included studies were similar. Jackson 2012 and Salisbury 2010 reported some differences.
No overall summary of participant details, gender or age. 
E9. Interventions evaluated in included systematic reviews
Systematic reviews included individual RCTs evaluating a range of interventions. Further description of the intervention is reported in Table E11 . Comments: a Aim of review to evaluate effectiveness of any form of intervention reported to reduce risk of CIP/CIM. Review also included non-physical rehabilitation interventions e.g. nutritional interventions, antioxidant therapy, hormone therapy, intravenous immunoglobulin. b Aim of review to identify therapies effective in improving long-term physical function. Review also included nonphysical rehabilitation interventions e.g. nutrition therapy, insulin therapy, nurse-led follow-up, spontaneous awakening and breathing trials, sedation holds, early tracheostomy. c Some interventions included other components including patient manuals, or cognitive therapy
E10. Assessment of methodological quality of included systematic reviews
All included systematic reviews underwent assessment using the PRISMA checklist 1 and AMSTAR tool 62 . Further details on the breakdown of PRISMA and AMSTAR scores are reported in Tables E12  and E13 . 
E11. Main findings and conclusions from included systematic reviews
The main findings and conclusions from included systematic reviews are reported in Table E14 . No effect with early physical therapy or EMS Not reported for 30d or 180d and no effect on hospital mortality with early Moderate quality evidence suggests potential benefit of early rehabilitation on CIP/CIM accompanied by reduced MV. Very low quality evidence suggests no effect of EMS.
